IL6 and infection: If IL-6 continues to increase or decreases by < 30% during treatment, it indicates poor therapeutic efficacy, requiring re-evaluation of the infection source (e.g., drug-resistant bacteria) or enhanced organ support (e.g., optimizing mechanical ventilation, initiating continuous renal replacement therapy (CRRT)); if it decreases by > 50% within one week, the intensity of treatment can be considered to be reduced to avoid over-intervention.